Cytosorbents (CTSO) Non Operating Income (2010 - 2026)

Cytosorbents has reported Non Operating Income for 17 years, with the latest figure at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 186.55% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 178.26% YoY), and the FY2025 full-year result was $6.1 million, up 203.22% from the prior year.
• Non Operating Income for Q1 2026 stood at -$2.1 million, down from -$1.1 million in the prior quarter.
• The five-year high for Non Operating Income was $5.6 million in Q2 2025, with the low at -$5.9 million in Q4 2024.
• Historically, Non Operating Income has averaged -$144371.1 across 5 years, with a median of -$724000.0 in 2024.
• The largest YoY upside for Non Operating Income was 1034.68% in 2022 against a maximum downside of 1120.28% in 2022.
• Cytosorbents' Non Operating Income stood at $4.5 million in 2022, then tumbled by 40.13% to $2.7 million in 2023, then tumbled by 317.73% to -$5.9 million in 2024, then surged by 81.03% to -$1.1 million in 2025, then tumbled by 87.5% to -$2.1 million in 2026.
• The last three Non Operating Income figures came in at -$2.1 million (Q1 2026), -$1.1 million (Q4 2025), and -$709000.0 (Q3 2025), per Business Quant data.